ArticleScientific reports2025
Development of novel Trichoderma bioformulations against Fusarium wilt of chickpea.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent Advances in Bioinoculant Formulations and Their Shelf-Life: A Review.Current microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chickpea wilt caused by Fusarium oxysporum f. sp. ciceris (FOC) is one of the most prevalent and damaging diseases in chickpea-growing areas. To manage FOC in an environmentally friendly and sustainable manner, the current studies were carried out in 2023 and 2024, and emulsion-based bioformulations of two potential Trichoderma isolates, T. harzianum AMUTH-1 and T. viride AMUTV-1 were prepared and tested under field conditions. For comparison, Pseudomonas fluorescens AMUPF-1, Grow-Power™ (commercial bioagent) and fungicide (carbendazim) were used as benchmarks. Field studies have shown that chickpea variety RVG-202 was highly susceptible to FOC and developed severe wilt at the vegetative stage. However, application of the emulsion-based bioformulation of T. harzianum significantly reduced the wilt severity (55%) and enhanced the plant growth and yield of chickpea by 23-33% and 31%, respectively. The effect of this emulsion formulation was also at par with fungicide, carbendazim and commercial bioagent, Grow-Power™. Hence, T. harzianum emulsion bioformulation may be considered as an alternative control measure for multi-pathogenic diseases of chickpea plants. This outcome could also be used to devise a suitable integrated management module to safeguard chickpea plants from the FOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.